ArticlePolymers2017
Acetal-Linked Paclitaxel Polymeric Prodrug Based on Functionalized mPEG-PCL Diblock Polymer for pH-Triggered Drug Delivery.
Article in Polymers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Designing drug delivery systems: the impact of structural order and disorder for optimized therapeutic outcomes.Nanomedicine (London, England) · 2026Review
- Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems.Pharmaceutics · 2026Review
- DOX-conjugated unimolecular micelles from benzaldehyde-functionalized star copolymer via metal-free ATRP for pH-responsive drug delivery.Science and technology of advanced materials · 2026Article
- Recent Advances in Polycaprolactones for Anticancer Drug Delivery.Pharmaceutics · 2023Review
- Smart Polymeric Nanoparticles in Cancer Immunotherapy.Pharmaceutics · 2023Review
- Review
- Recent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy.Frontiers in bioengineering and biotechnology · 2022Review
- Recent Advances in Stimuli-Sensitive Amphiphilic Polymer-Paclitaxel Prodrugs.Frontiers in bioengineering and biotechnology · 2022Review
- Nanoformulations of Ursolic Acid: A Modern Natural Anticancer Molecule.Frontiers in pharmacology · 2021Review
- A Compressive Review about TaxolMolecules (Basel, Switzerland) · 2020Review
- pH-Sensitive Biomaterials for Drug Delivery.Molecules (Basel, Switzerland) · 2020Review
- Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis.Polymers · 2020Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The differences in micro-environment between cancer cells and the normal ones offer the possibility to develop stimuli-responsive drug-delivery systems for overcoming the drawbacks in the clinical use of anticancer drugs, such as paclitaxel, doxorubicin, and etc. Hence, we developed a novel endosomal pH-sensitive paclitaxel (PTX) prodrug micelles based on functionalized poly(ethylene glycol)-poly(ε-caprolactone) (mPEG-PCL) diblock polymer with an acid-cleavable acetal (Ace) linkage (mPEG-PCL-Ace-PTX). The mPEG-PCL-Ace-PTX₅ with a high drug content of 23.5 wt % was self-assembled in phosphate buffer (pH 7.4, 10 mM) into nanosized micelles with an average diameter of 68.5 nm. The in vitro release studies demonstrated that mPEG-PCL-Ace-PTX₅ micelles was highly pH-sensitive, in which 16.8%, 32.8%, and 48.2% of parent free PTX was released from mPEG-PCL-Ace-PTX₅ micelles in 48 h at pH 7.4, 6.0, and 5.0, respectively. Thiazolyl Blue Tetrazolium Bromide (MTT) assays suggested that the pH-sensitive PTX prodrug micelles displayed higher therapeutic efficacy against MCF-7 cells compared with free PTX. Therefore, the PTX prodrug micelles with acetal bond may offer a promising strategy for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.